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The susceptibility of the normal cellular prion protein isoform, cellular prion protein (PrPC),
to proteolytic digestion has been well documented. In addition, a link between PrPC and
the cytosolic protease, calpain, has been reported although the specifics of the interaction
remain unclear.We performed in vitro and in cell-based studies to examine this relationship.
We observed that human recombinant PrP (HrPrP) was readily cleaved by calpain-1 and -2,
and we have identified and defined the targeted cleavage sites. In contrast, HrPrP was resis-
tant to caspase-3 digestion. Unexpectedly, when brain lysates from PrPC-expressing mice
were treated with calpain, no appreciable loss of the intact PrPC, nor the appearance of PrPC
breakdown products (BDPs) were observed, even though alpha II-spectrin was converted
to its signature calpain-induced BDPs. In addition, when rat cerebrocortical neuronal cul-
tures (RtCNC) were subjected to the two neurotoxins at subacute levels, maitotoxin (MTX)
and N -methyl-D-aspartate (NMDA), PrPC-BDPs were also not detectable. However, a novel
finding from these cell-based studies is that apparently full-length, mature PrPC is released
into culture media from RtCNC challenged with subacute doses of MTX and NMDA. Cal-
pain inhibitor SNJ-1945 and caspase inhibitor IDN-6556 did not attenuate the release of
PrPC. Similarly, the lysosomal protease inhibitor, NH4Cl, and the proteasome inhibitor, lac-
tacystin, did not significantly alter the integrity of PrPC or its release from the RtCNC. In
conclusion, rat neuronal PrPC is not a significant target for proteolytic modifications during
MTX and NMDA neurotoxic challenges. However, the robust neurotoxin-mediated release
of full-length PrPC into the cell culture media suggests an unidentified neuroprotective
mechanism for PrPC.
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INTRODUCTION
The cellular prion protein (PrPC) is a host-coded, glycosylphos-
phatidylinositol (GPI)-anchored (linked through Serine-231)
transmembrane glycoprotein found in all mammalian cells with
relatively high levels in the central nervous system (CNS; Kret-
zschmar et al., 1986; Moudjou et al., 2001) particularly at neuronal
synapses (Sales et al., 1998). Following prion agent infection, the
protease-sensitive PrPC is converted into the conformationally
altered, disease-specific PrPSc isoform which is partially protease-
resistant (Riesner, 2003). In contrast to PrPSc, PrPC is soluble in
detergents and sensitive to proteolytic digestion by PK.
Although PrPC has been associated with numerous cellular
roles associated with cell signaling and/or neuroprotective func-
tions, the specific physiologic function of PrPC remains unclear.
PrPC neuroprotective functions that have been demonstrated both
in vivo and in vitro (Westergard et al., 2007; Linden et al., 2008)
include: cytoprotective activity against internal or environmental
stresses that initiate apoptosis and oxidative stress, ionic channel
modulation, transmembrane signaling, as well as formation and
maintenance of synapses. PrPC not only protects neurons in vitro
and in vivo from N -methyl-d-aspartate (NMDA)-evoked excito-
toxicity (Khosravani et al., 2008) but also against oxidative stress
and plays a role in Cu/Zn superoxide dismutase activity (Brown
and Besinger, 1998; Wong et al., 2000; Brown et al., 2002).
PrPC and PrPSc are subject to diverse intracellular proteolytic
processing events (Pan et al., 1992; Harris et al., 1993; Tarabou-
los et al., 1995). PrPC undergoes proteolytic cleavage at amino
acids 110/111 within a segment of conserved hydrophobic amino
acids to produce a ∼17 kDa C-terminal fragment referred to as
C1. Studies suggest that ADAM/TACE (a disintegrin and met-
alloprotease/tumor necrosis factor α-converting enzyme) matrix
metalloproteases may be responsible for the generation of the
C1 fragment (Vincent et al., 2001). Previous studies using post-
mortem human brain extracts demonstrated that the disease-
associated PrP in Creutzfeldt–Jakob disease (CJD) brains is cleaved
by a cellular protease to generate a C-terminal fragment, referred
to as C2, which has the same molecular weight as PrP27–30, the
protease-resistant core of PrPSc (Chen et al., 1995). Dron et al.
(2010) showed that the full-length PrPSc to C2 ratio varied such
that uncleaved PrPSc accumulated in primary neurons and brain
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whereas PrPSc processing occurred in infected Rov and MovS
cells. They also found that cathepsin, but not calpain, inhibitors
markedly reduced C2 formation. In contrast, studies by Yadavalli
et al. (2004) using persistently infected scrapie mouse brain cells or
persistently infected scrapie N2a cells indicate that endoproteolytic
cleavage of PrPSc is facilitated by calpains.
Wang et al. (2005) showed that in several cell lines and in
primary mouse cortical neurons PrPC was normally degraded
by the proteasome but could alternatively be targeted by cal-
pain. Furthermore, Hachiya et al. (2011) reported that the calpain
inhibitor, calpastatin, dramatically inhibited normal endoprote-
olysis of PrPC in N2a cells. Also, they found that the molecular
weight of PrPC fragments generated by spontaneous proteolysis
was identical to those produced when PrPC translated in vitro
was exposed to exogenously added calpain. Due to these conflict-
ing data regarding the potential vulnerability of PrPC to calpain
and other cytosolic proteases, we performed in vitro and in cell-
based studies using rat primary cerebrocortical neuronal cultures
(RtCNC). We describe the possibility of a novel neuroprotective
function for calpain-resistant, full-length PrPC that is shed from
neuronal cells in response to neurotoxic challenge.
MATERIALS AND METHODS
MATERIALS
Secondary antibodies were purchased from Novagen (Philadel-
phia, PA, USA). Maitotoxin (MTX) and clasto-lactacystin-β-
lactone from Calbiochem (Billerica, MA, USA). NMDA, NH4Cl,
and other chemical reagents were from Sigma-Aldrich (St. Louis,
MO, USA). Human recombinant calpain-1, rat calpain-2, and
human recombinant caspase-3 were from EMD Millipore Bio-
sciences (Billerica, MA, USA). Calpain inhibitor SNJ-1945 (SNJ)
was a gift from Senju Pharmaceutical (Shimazawa et al., 2010)
while pan caspase inhibitor IDN-6556 (IDN) was synthesized
in-house at Banyan Laboratories according to published meth-
ods (Hoglen et al., 2004). Cell culture grade reagents were from
Invitrogen (Grand Island, NY, USA). Anti-alpha II (αII)-spectrin
monoclonal antibody (Mab) was purchased from Enzo Life Sci-
ences (Farmingdale, NY, USA) while anti-PrP Mabs 7E4, E11, and
D8 were generated by Dr. Rubenstein at SUNY Downstate Med-
ical Center. Since rat PrP is not commercially available. We used
human recombinant PrP (HrPrP) as a substitute. The human PrP
(accession # AAH22532) and rat PrP (accession # BAA08790)
show a high level of homology. Purified E. coli HrPrP (residues
23–231 based on the human PrP sequence mimicked signal pep-
tidase removal of the first 22 residues) containing an N-terminal
(His)6-tag fusion protein, designated (His)6-HrPrP, was purchased
from Abnova (Walnut, CA, USA) and EMD Millipore Bioscience
(Billerica, MA, USA).
RtCNC PREPARATION AND NEUROTOXIN CHALLENGES
The Institutional Animal Care and Use Committee at the Univer-
sity of Florida (Gainesville, FL, USA) approved the use of timed
pregnant rats for these studies and all animal use followed the
appropriate regulatory standards. RtCNC were prepared from fetal
Sprague Dawley rats as previously described (Wang et al., 1996).
These neuronal-enriched cultures were maintained in vitro and
allowed to mature for 10 days. Cells were then either untreated
(control), exposed to dimethylsulfoxide (DMSO) vehicle alone, or
challenged with neurotoxins (0.3 nM MTX or 300µM NMDA)
for 24 h in the absence or presence of lysosomal neutralizing agent
NH4Cl (10 mM), proteasome inhibitor lactacystin (10µM), SNJ
(30µM), or IDN (30µM). Inhibitors were added 1 h prior to
addition of neurotoxic drug. All treatments were performed in
serum-free Dulbecco’s Minimal Essential Medium in a volume
of 300µl per well of a 12-well cell culture plate. DMSO vehicle
alone as well as all drug treatments had no adverse affects on cell
morphology and viability for at least 72 h (data not shown). After
treatments, conditioned media was collected from each sample
into separate tubes on ice and clarified by microcentrifugation
at 10,000× g for 5 min. Supernatants (“conditioned cell culture
media”) were immediately frozen at −80˚C.
Soluble cell extracts were generated by gently shaking cells for
2 h at 4˚C in 1x Triton X-100 lysis buffer (20 mM Tris-HCl, pH 7.4,
150 mM NaCl, 5 mM EDTA, 5 mM EGTA, 1% Triton X-100, 1 mM
dithiothreitol (DTT), 1x Roche complete protease inhibitor cock-
tail, 1x phosphatase inhibitors (Sigma). This treatment resulted
in complete cell lysis by microscopic observations. Extracts were
transferred to 1.5 ml microcentrifuge tubes, spun at 10,000×G for
10 min at 4˚C to generate insoluble pellets, and both were stored
at −80˚C. The insoluble pellets were then extracted and resus-
pended in 1x RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl,
5 mM EDTA, 0.5% Igepal CA-630, 0.5% sodium deoxycholate,
0.2% SDS) supplemented with 1x protease inhibitor cocktail and
disrupted by cup horn sonication (Sonics Vibracell, Newtown,
CT, USA) for three 10 s. on−10 s. off cycles (20% power output).
The samples were microcentrifuged at 10,000×G for 10 min at
4˚C and the supernatants, labeled as insoluble cell extracts, were
stored at−80˚C. Unless otherwise stated, 50µg each of soluble and
insoluble fractions and 20µl conditioned media were analyzed by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and western
blotting.
For Endoglycosidase H (Endo H) treatment, combined 25µl
of samples (soluble or insoluble cell extracts, conditioned cell cul-
ture media) with 3µl of 10x glycoprotein denaturing buffer (5%
SDS, 0.4 M DTT) and 2µl of distilled water. Boiled for 10 min to
denature sample and allowed to cool. Next, added a final concen-
tration of 0.05 M sodium citrate (pH 5.5) and 500 units of Endo
H (New England BioLabs, Ipswich, MA, USA) in a total final reac-
tion volume of 40µl. Incubated the reaction for 2 h at 37˚C and
stopped by boiling for 4 min in 1x SDS-PAGE sample buffer. The
samples were electrophoresed on 12% gels and immunoblotted as
described below.
MOUSE BRAIN LYSATE PREPARATION
Adult naive mice were anesthetized and immediately sacrificed
by decapitation. Brain was exposed and flushed with ice-cold
phosphate-buffered saline (PBS). The bilateral cortex was imme-
diately removed, rinsed with ice-cold PBS, and placed into a 1.5 ml
microcentrifuge or cryofreeze tube, snap-frozen in liquid nitrogen
and stored at −80˚C until used. For brain lysates, samples were
pulverized to a fine powder with a mortar and pestle set into dry
ice. The pulverized brain tissue powder was then treated for 90 min
at 4˚C with 1X Triton X-100 lysis buffer. The brain lysates were then
centrifuged at 8,000×G for 5 min at 4˚C and the supernatants
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were snap-frozen in liquid nitrogen and stored at −80˚C. Protein
concentrations of samples were determined using the Bio-Rad DC
protein assay.
SDS-PAGE, IMMUNOBLOTTING, AND STATISTICS
Brain tissue extracts (20µg), soluble and insoluble RtCNC cell
lysate fractions (50µg), and conditioned media (20µl) were sep-
arated by SDS-PAGE (10–20% gradient gels for HrPrP, 12% gels
for PrPC, 4–20% gradient gels for spectrin), and transferred to
PVDF membrane by iBlot (Invitrogen) or the semi-dry method.
Blots were blocked in 5% non-fat dry milk in Tris-buffered saline
containing 0.2% Tween-20, pH 7.4 (TBST), and then probed with
primary Mabs (anti-PrP Mabs 7E4, E11, or D8 at 1µg/ml, and
anti-αII-spectrin at 0.05µg/ml) overnight. The bands were either
visualized by chemiluminescence using a goat anti-mouse IgG-
horseradish peroxidase conjugate (ECL Super Signal West Dura,
Pierce) or by incubation with biotin-conjugated secondary anti-
body followed by streptavidin-alkaline phosphatase conjugate and
developed with NBT-BCIP substrate. Quantification of PrPC, as
represented by the non-, mono-, and deglycosylated isoforms of
the protein, was performed by densitometric analysis using NIH
Image J software v. 1.34. In SDS-PAGE and Western blot experi-
ments, it is noted for in vitro protein digestion, we loaded the same
amount of starting protein concentration before digestion and
made sure equal sample volume was loaded. For cell lysate stud-
ies, we routinely run Ponceau S staining and/or β-actin to ensure
protein loading is the same for each lane. Unless stated otherwise,
all data shown are representative of three separate experiments.
IN VITRO PROTEOLYSIS OF (His)6-HrPrP OR PrPC IN MOUSE BRAIN
LYSATE
A 100µg aliquot of (His)6-HrPrP or mouse brain lysate was
subjected to calpain-1, calpain-2, or caspase-3 digestion (each at
a protease:substrate ratio of 1:50). For (His)6-HrPrP, following
SDS-PAGE, the proteins were transferred to PVDF membrane
and stained with Coomassie Brilliant Blue (0.6% wt/vol in 1:1
methanol:H2O) for 15 s followed by methanol:H2O (1:1) destain-
ing until protein bands were visible. After soaking in water, PVDF
membranes were air-dried. Major breakdown products (BDPs)
were identified by N-terminal microsequencing performed at the
Interdisciplinary Center for Biotechnology Research (University
of Florida, Gainesville, FL, USA). Alternatively, a 5µg aliquot of
(His)6-HrPrP was digested with calpain-2 and 0.5µg protein were
analyzed per lane.
RESULTS
CALPAIN PROCESSING OF HrPrP AND IDENTIFICATION OF MAJOR
CALPAIN CLEAVAGE SITES
The issue of PrPC vulnerability to calpain proteolysis was first
addressed. The E. coli expressed (His)6-HrPrP was subjected to
calpain-1, calpain-2, and caspase-3 digestion (Figure 1). Calpain-1
and calpain-2 are the two dominant isoforms of calpain in
neurons. Caspase-3 treatment was also examined since it has
previously been shown that many calpain substrates also serve
as substrates for caspase-3 (Wang, 2000).
Following SDS-PAGE and Coomassie blue staining, intact
(His)6-HrPrP migrated as an ∼30 kDa protein, while four major
FIGURE 1 | HrPrP vulnerability to calpain-1, -2 digestion with
identification of major cleavage sites. E. coli expressed recombinant
N-terminal (His)6-tag fusion protein with human PrPC residues 23–231
(Human prion protein; accession # NP 898902) was subjected to
calpain-1, calpain-2, and caspase-3 digestion (1:50 protease:substrate
ratio). Following SDS-PAGE, proteins were transferred to PVDF
membrane and stained with Coomassie blue. (A) Major BDPs were
identified by N-terminal microsequencing. (B) Based on the PrPC amino
acid sequence the cleavage sites are identified and depicted by
downward arrows. The new N-terminal sequences are identified in bold
and the calpain recognition P1–P2 sequences are underlined and in
bold (C).
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BDPs of molecular weights 24, 18, 13, 11 kDa were observed
when (His)6-HrPrP was digested by either calpain-1 or calpain-
2 (Figure 1A). In contrast, caspase-3 digestion yielded no
BDPs or observable reduction of intact (His)6-HrPrP inten-
sity (Figure 1A). N-terminal microsequencing of these pro-
teins identified PrP-BDP-18 and PrP-BDP-11 kDa as N-terminal
PrP products each containing an intact His-tagged N-terminus
(Figure 1B). PrP-BDP-24 kDa contained a new N-terminus
beginning at residue 40 (S40PGGNRYPPQGG), while PrP-BDP-
13 kDa possessed a new N-terminus beginning at residue 131
(S131AMSPRIIHFGSDY; Figures 1B,C). Thus the two major cal-
pain cleavage sites were identified as between PrP residues 40–41
and residues 130–131(Figure 1C).
Immunostaining was performed to further characterize
calpain-2 induced proteolytic cleavage of (His)6-HrPrP (Figure 2).
(His)6-HrPrP was digested with calpain-2 using three pro-
tease:substrate ratios of 1:200, 1:50, and 1:5 with the last condition
causing the most extensive PrP hydrolysis. Treated protein sam-
ples (500 ng) were analyzed by western blotting using PrP-specific
Mabs 7E4 and E11 (Figure 2A) as well as a rabbit polyclonal
anti-His tag antibody. As previously reported (Chang et al., 2012)
and depicted in Figure 2B, the epitope for Mab 7E4 are PrP
residues 29–35. Since one of the targeted calpain cleavage sites
is residues 40–41. MAb 7E4 antibody detected epitope residue 29–
35 which is N-terminal to the first calpain cleavage site (between
residue 40–41), it is thus truncated off as a very small fragment (less
than 4 kDa) thus not readily observable on the blot (Figure 2A).
Instead, we observed a protease dose-dependent reduction
of intact (His)6-HrPrP indicative of proteolysis (Figure 2A).
Anti-His tag antibody, which detects the N-terminal (His)6-tag,
produced essentially the same results as Mab7E4 (data not shown).
In contrast, anti-PrP Mab E11 targets two internal epitopes (aa
95–111 and aa 138–145; Figure 2B) and upon cleavage by calpain-
2, two fragments of 26 and 18 kDa are readily observed in addition
to the reduction of intact PrP (Figure 2A). These results further
confirmed that (His)6-HrPrP can be readily digested by calpain-2.
VULNERABILITY OF ENDOGENOUS BRAIN PrPC TO CALPAIN
PROTEOLYSIS
Previous studies (Wang et al., 2005; Dron et al., 2010) have showed
that PrP in different tissues or cell types might have variable
vulnerability to endogenous proteolysis. Thus we next sought to
examine the vulnerability of native PrPC to calpain and caspase-
3 proteolysis in vitro with mouse brain lysate under digestion
conditions similar to that described for (His)6-HrPrP. We observed
the characteristic calpain-mediated αII-spectrin BDPs (SBDPs)
SBDP150 and SBDP145, while caspase-3 generated the character-
istic SBDP150i and SBDP120 (Figure 3A), as has been previously
described (Zhang et al., 2009). In contrast, only two very minor
BDPs (30 and 28 kDa) of the 33–35 kDa PrPC were observed by
FIGURE 2 | Characterization of HrPrP proteolysis by calpain-2.
(A) Recombinant N-terminal (His)6-tag PrP fusion protein was untreated
(control) digested with calpain-2 (protease:substrate ratios of 1:200, 1:50,
1:5). Five hundred nanograms of protein was then subjected to SDS-PAGE
and western blotting. Three antibodies were used. Anti-PrP Mabs 7E4, E11,
and anti-His tag antibody. Rainbow molecular weight markers were used. (B)
Schematic of PrP showing the positions of the two calpain cleavage sites and
the anti-PrP Mab epitopes.
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western blotting when immunostained with anti-PrP Mab E11
(Figure 3B). No PrPC-BDPs were observed following immunos-
taining with Mab 7E4 (data not shown). This result strongly
suggests that endogenous PrPC, unlike (His)6-HrPrP, is relatively
resistant to calpain proteolysis.
INTEGRITY AND LOCALIZATION OF PRPC IN RtCNC SUBJECTED TO
NEUROTOXIC CHALLENGES
We next sought to examine the integrity and localization of PrPC
in RtCNC after they were subjected to neurotoxic challenges. Neu-
rotoxin calcium channel opener MTX (0.3 nM) or excitotoxin
glutamate analog NMDA (300µM) were selected since it has pre-
viously been shown that these challenges induce strong calpain
and mixed calpain/caspase-3 activation (Wang et al., 1996; Zhang
et al., 2009).
PrPC could reside in membrane-associated fractions or in sol-
uble cytosolic fractions. We therefore performed cell extractions
which allowed us to examine soluble and insoluble cellular pro-
teins separately by initially lysing cells with mild neutral detergents
followed by extraction of the remaining insoluble proteins with
anionic detergents. Thus soluble and insoluble fractions (50µg
each) and conditioned cell culture media (20µl), were analyzed
by western blotting using Mab D8 (Figure 4). In the insoluble
fraction of control cortical cultures we observed that the bulk of
the PrPC was full-length (33–35 kDa) and a protein that migrated
at 20 kDa (most likely the deglycosylated form). Small amount of
FIGURE 3 | Relative resistance of PrPC from mouse brain lysate to
calpain proteolysis. Lysate from naïve mouse brains were prepared and
digested with calpain-1, -2, or caspase-3 as described in section “Materials
and Methods.” Aliquots of the untreated and treated lysates were then
electrophoresed, western blotted, and immunostained with either
anti-αII-spectrin Ab (A) or with anti-PrP Mab E11. (B) Characteristic
calpain-generated SBDP150 and SBDP145 as well as caspase-3 generated
SBDP150i and SBDP120 are indicated. No PrPC-BDPs were observed
following the treatments with Mab 7E4 (data not shown).
33–35 kDa, and to much lesser extent the 20 kDa form, were also
detected in the soluble fraction of control cultures. In contrast,
there were almost undetectable levels of PrPC in the conditioned
cell culture media (Figure 4). MTX has previously been shown to
be a potent calpain activator due to the extreme calcium influx
it induces (Wang et al., 1996; Zhang et al., 2009). Yet, with MTX
treatment of RtCNC, there was no significant alteration of PrPC
patterns in either insoluble or soluble fractions as far as the 33–35
and 20 kDa species are concerned (Figure 4A). There was,however,
a minor increase of 12 kDa form (possibly a PrPC BDP). Similarly,
NMDA challenge did not alter the pattern of PrPC in both soluble
or insoluble cellular fractions with the exception that the 20 kDa
protein band appeared to be slightly elevated. However, rather
unexpectedly, there was a distinct presence of the intact PrPC in
conditioned cell culture media only with NMDA or MTX treat-
ment, when compared to control. Given that only 20µl of a total
of 500µl conditioned cell culture media was examined, the overall
increase of PrPC was relatively substantial (Figure 4A). When we
added concentrated RIPA buffer to the whole cell culture well to
extract and recover the insoluble, soluble fractions, and cell con-
ditioned media with or without MTX or NMDA treatment, we
observed that the overall levels of PrPC remained the same, thus
ruling out the increased PrP in cell media being due to overex-
pression and increased production of PrPC by the cells (results
not shown). Thus we concluded that both neurotoxin treatments
in fact resulted in increased release of 33–35 kDa PrPC into the
media (Figure 4). Following MTX exposure, Endo H treatment
of the soluble and insoluble cell extracts and the conditioned cell
culture media prior to electrophoresis and western blotting did
not result in either altered PrPC migration or the immunostain-
ing patterns compared to untreated controls (data not shown)
FIGURE 4 | Release of full-length PrPC into culture media from RtCNC
challenged with neurotoxins MTX and NMDA. RtCNC were either
untreated (control; Ctrl) or challenged with MTX or NMDA. (A) Soluble and
insoluble cell fractions and conditioned cell culture media were analyzed by
SDS-PAGE followed by western blotting and immunostaining with Mab D8.
(B) Soluble cell fractions were also analyzed with anti-αll spectrin Mab to
probe the formation of SBDPs (SBDP150 by calpain and SBDP120 by
caspase-3). Blots are representative of four separate experiments.
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suggesting that these are fully processed and mature forms of the
protein. To confirm that calpain was indeed activated following
MTX- and NMDA-treatments, soluble fractions were also ana-
lyzed with anti-αII-spectrin Mab to assess the formation of SBDPs.
In comparison to control conditions, a major reduction of intact
αII-spectrin with MTX and NMDA-treatments was observed. Fur-
thermore, calpain-mediated SBDP150/145 bands were prominent
under these neurotoxic conditions (Figure 4B).
We examined if the unexpected release of full-length PrPC
induced by the neurotoxins MTX and NMDA could be atten-
uated by calpain or caspase-3 inhibition. RtCNC were either
untreated (control) or challenged with MTX or NMDA, in the
absence or presence of SNJ or IDN (Figure 5). PrPC release was
again monitored by immunoblotting with Mab D8. Similar to
Figure 4, we confirmed that media from both MTX and NMDA
challenged groups contained significantly greater PrPC release
compared to control (p< 0.05). We also noted that the MTX-
induced PrPC release levels were significantly higher than those by
NMDA-induced release (p< 0.05). Neither SNJ nor IDN inhibi-
tion significantly altered MTX- or NMDA-induced PrPC release
levels, respectively (Figures 5 and 6).
Lastly, we investigated if the integrity of PrPC or its distrib-
ution in soluble, insoluble, or media fractions could be altered
by inhibition of additional cellular proteases. Here we chose the
MTX challenge since it produced the most robust PrPC response
(Figure 5). RtCNC were either untreated (control) or challenged
with MTX in the absence or presence of lysosomal neutraliz-
ing agent (10 mM NH4Cl), proteasome inhibitor (10µM lac-
tacystin), calpain inhibitor (30µM SNJ), or caspase inhibitor
FIGURE 5 | Quantification of release of full-length PrPC into culture
media from RtCNC challenged with neurotoxin MTX and NMDA.
RtCNC were either untreated (control) or challenged with MTX or NMDA in
the absence or presence of SNJ or IDN. Full-length PrPC release was
detected by analyzing conditioned cell culture media by SDS-PAGE and
western blotting using anti-PrP Mab D8. Quantitation of PrPC
immunostaining was performed using Image J as described in the
Methods section. Data are representative of up to seven measurements
per group from three separate experiments. Values are expressed as
mean± standard error. * indicates NMDA or MTX challenge groups have
significantly higher PrPC release compared to control (p<0.05). # indicates
MTX challenge group has significantly higher PrPC release compared to
NMDA challenge group (p<0.05). Neither inhibitor treatment significantly
altered MTX- or NMDA-induced PrPC release levels, respectively.
(30µM IDN). Soluble and insoluble fractions (50µg each) and
conditioned cell culture media (20µl) were analyzed by west-
ern blotting with Mab D8. MTX did not alter PrPC integrity as
demonstrated by the unmodified pattern of protein banding in
soluble and insoluble cell fractions (Figure 6). However, MTX
treatment did cause dramatic release of full-length PrPC into cell
culture media, consistent with our previous findings (Figure 6).
None of the protease inhibitor treatments significantly altered
full-length PrPC levels in either cell fractions or attenuated the
MTX-induced PrPC release into the media (Figure 6B). Thus, full-
length PrPC release from MTX-challenged cortical neurons into
cell culture media appears to be independent of cellular protease
activation.
DISCUSSION
There exists a potential vulnerability of PrPC and PrPSc to pro-
cessing by calpain and other cytosolic proteases (Yadavalli et al.,
2004; Wang et al., 2005; Hachiya et al., 2011). However, conflicting
data exists especially regarding PrPC. In this study, we performed
in vitro and in cell-based studies using primary RtCNC to further
examine this issue. (His)6-HrPrP was cleaved by calpain-1 and -2
in vitro and the two targeted cleavage sites were identified between
resides Gly40-Ser41 and residues Gly130-Ser131. (His)6-HrPrP,
however, was resistant to caspase-3 digestion. In contrast, PrPC in
brain cell lysates was fairly resistant to calpain digestion while αII-
spectrin was readily converted to its signature calpain-generated
BDPs. The amino acid sequences for human and rat PrP are iden-
tical at the calpain targeted HrPrP cleavage sites. Therefore, the
differences in calpain sensitivity between HrPrP and the rat PrP
cell cultures is probably the result of protein folding differences and
target site accessibility of the recombinant protein compared to the
native rat PrPC. Additionally, the detergent solubilization of HrPrP
may contribute to calpain target site availability when compared
to the more natural environment of the cell membrane-associated
rat PrPC.
Also, when RtCNC were subjected to the MTX and NMDA neu-
rotoxins, proteolysis of PrPC was again minimal. Unexpectedly,
these challenges resulted in the release of presumably full-length,
mature PrPC into the media. Treatment of the RtCNC with SNJ,
IDN, NH4Cl, or lactacystin did not significantly alter the integrity
of cellular PrPC or its release into conditioned cell culture media.
Previous studies (Yadavalli et al., 2004) have shown that both
PrPSc and PrPC isoforms in CJD brain are cleaved by cellular pro-
teases to generate a C-terminal fragment, referred to as C2 and
that one of these proteases is likely to be calpain. Hachiya et al.
(2011) found that the molecular weight of PrPC fragments gener-
ated by spontaneous proteolysis in mouse N2a cells was identical
to the calpain-generated fragments of in vitro-translated PrPC
and overexpression of the calpain inhibitor, calpastatin, drasti-
cally inhibited normal endoproteolysis of PrPC in N2a cells. In
addition, Wang et al. (2005) showed that in several cell lines and
primary mouse cortical neurons, a portion of the endogenous
PrPC was degraded by the proteasome in the cytosol. Thus we
initially hypothesized that PrPC would be vulnerable to calpain
cleavage in RtCNC and rat brain lysate but were surprised to find
that was not the case. Further, data mining studies by Dron et al.
(2010) reported that in primary neurons and brain tissue, PrPSc
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FIGURE 6 | Integrity of PrPC in RtCNC and its release into culture media
upon MTX challenge is not significantly altered by protease inhibition.
(A) RtCNC were either untreated (control) or challenged with MTX in the
absence or presence of NH4Cl, lactacystin (lacta), SNJ, or IDN. Soluble and
insoluble cell fractions and conditioned cell culture media were analyzed by
SDS-PAGE and western blotting using anti-PrP Mab D8. Blots are
representative of three separate experiments. (B) Quantification of PrPC band
(33–35 kDa) intensity in the fractions as described in (A). Values are expressed
as mean± standard error. MTX did not alter the levels of PrPC in the soluble or
insoluble cell extracts. None of the protease inhibitor treatments altered PrPC
levels in either soluble or insoluble cell fractions. The MTX-induced PrPC
release into the media was not attenuated by any of the inhibitor treatments.
accumulated predominantly as uncleaved species. Thus, this PrPSc
data is consistent with our PrPC data presented here.
Taken together, we observed that PrPC in RtCNC was not
a significant target for proteolytic modifications during neuro-
toxic challenges. Yet, the current study is the first report that
describes the release or shedding of full-length PrPC from the
cell upon neurotoxic challenges. It is possible that this is a pro-
tective response of the cells to neurotoxic threats. Importantly,
the release of full-length PrPC as a response to neurotoxins might
have a physiological function involved in neuroprotection such
as stimulating cell activation and/or release of trophic factors. It
has been shown that in transgenic mice, PrPC overexpression is
neuroprotective while mice that did not express PrPC were more
susceptible to neurotoxicity or neurodegeneration (Westergard
et al., 2007).
A protease-mediated physiological cleavage near the C-
terminus of PrPC in close proximity to its GPI-anchor has been
reported in neurons and lymphoid cells (Borchelt et al., 1993). This
resulted in the release of the almost full-length protein from the
plasma membrane. This soluble form of shedded PrPC was also
found in human CSF (Tagliavini et al., 1992) and blood (Perini
et al., 1996; MacGregor et al., 1999; Parizek et al., 2001) indi-
cating physiological relevance. Cell culture experiments identified
ADAM10, along with a regulatory role of ADAM9, as the active
components responsible for the shedding of nearly full-length
PrPC from the cell surface (Cisse et al., 2005; Taylor et al., 2009;
Tousseyn et al., 2009; Moss et al., 2011). In vivo studies also con-
firmed the role of ADAM10 in PrPC shedding (Altmeppen et al.,
2011).
As Altmeppen et al. (2012) recently articulated elegantly that
when compared to membrane-associated PrPC, shed PrPC may
have distinct functions or activities (Harris et al., 1993; Parizek
et al., 2001; Altmeppen et al., 2011). Amyloid precursor protein
(APP) can be processed either through an amyloidogenic pathway
to generate Aβ or through a non-amyloidogenic pathway to block
Aβ production and generate soluble APPα (sAPPα). Aβ1-42 accu-
mulation in the brain has been shown to impair neuronal function
(Hu et al., 2009), while generation of sAPPα is known to play neu-
roprotective and neurotrophic roles (Cheng et al., 2002; Stein et al.,
2004). De Felice et al. (2007) reported that Aβ oligomers caused
the formation of neuronal-damaging reactive oxygen species that
was mediated by NMDA receptors (NMDAR). Further, PrPC has
been reported to provide a neuroprotective role by its ability to
limit NMDAR excitotoxicity (Khosravani et al., 2008) while both
the presence of Aβ1-42 and PrPC inactivation caused the NMDAR
neurotoxicity (You et al., 2012).
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Thus taken these concepts together, and relating them to neu-
rodestructive (Aβ) and neuroprotective (sAPPα) roles of processed
APP, the increased release of shed PrPC, could represent a self-
defense mechanism to preserve those neurons or neighboring
neurons under neurotoxic attacks (Altmeppen et al., 2012). Here,
it is tempting to suggest that similar or same neuroprotective
mechanisms might be at play in our MTX and NMDA challenge
paradigm in RtCNC, thus explaining the observed PrPC release.
It is possible that exposure of neuronal cells to neurotoxins acti-
vates ADAM10 causing PrPC shedding. This shed PrPC could, in
turn, bind to neurotoxins thereby reducing their direct contact
with cells. Our laboratories are now in the process of furthering
work in this direction.
Roberts et al. (2010) demonstrated that PrPC is signifi-
cantly increased in the cerebrospinal fluid of HIV-1 infected
individuals with cognitive impairment. Their studies indicate
that since the increase of PrPC is not a generalized phenome-
non of neuronal injury or neuroinflammation, it can therefore
serve as a useful biomarker to monitor disease progression in
HIV-infected individuals. Although the release of PrPC in response
to neurotoxin challenge in vitro is interesting and may offer
some insight as to its neuroprotective mechanism, its ability to
serve a similar function and/or as a CNS biomarker follow-
ing brain insult is attractive but speculative and requires fur-
ther investigation. The release of proteins (e.g., SBDPs, UCH-
L1) from neuronal cultures subjected to neurotoxic challenges
have not only been reported previously (Dutta et al., 2002;
Siman et al., 2004) but have also proven to be useful CNS bio-
markers after traumatic or ischemic brain injury (Zhang et al.,
2011).
ACKNOWLEDGMENTS
The authors would like to thank Drs. Ming Cheng Liu and Wen-
rong Zheng (formerly of Banyan Laboratories) for their techni-
cal help in cleavage site identification experiments and neuronal
culture studies. This work was supported by a grant from the
Department of Defense (W81XWH-11-2-0069/DM102153) and
the SUNY Downstate Medical Center.
REFERENCES
Altmeppen, H. C., Prox, J., Puig, B.,
Kluth, M. A., Bernreuther, C.,
Thurm, D., et al. (2011). Lack of a-
disintegrin-and-metalloproteinase
ADAM10 leads to intracellular
accumulation and loss of shedding
of the cellular prion protein in vivo.
Mol. Neurodegener. 6, 36.
Altmeppen, H. C., Puig, B., Dohler, F.,
Thurm, D. K., Falker, C., Krasemann,
S., et al. (2012). Proteolytic process-
ing of the prion protein in health and
disease. Am. J. Neurodegener. Dis. 1,
15–31.
Borchelt, D. R., Rogers, M., Stahl,
N., Telling, G., and Prusiner, S. B.
(1993). Release of the cellular prion
protein from cultured cells after
loss of its glycoinositol phospholipid
anchor. Glycobiology 3, 319–329.
Brown, D. R., and Besinger, A. (1998).
Prion protein expression and super-
oxide dismutase activity. Biochem. J.
334, 423–429.
Brown, D. R., Nicholas, R. S., and
Canevari, L. (2002). Lack of prion
protein expression results in a neu-
ronal phenotype sensitive to stress. J.
Neurosci. Res. 67, 211–224.
Chang, B., Petersen, R., Wisniewski, T.,
and Rubenstein, R. (2012). Influence
of Mabs on PrPSc formation using
in vitro and cell-free systems. PLoS
ONE 7, e41626. doi: 10.1371/jour-
nal.pone.0041626
Chen, S. G., Teplow, D. B., Parchi,
P., Teller, J. K., Gambetti, P., and
Autilio-Gambetti, L. (1995). Trun-
cated forms of the human prion
protein in normal brain and in
prion diseases. J. Biol. Chem. 270,
19173–19180.
Cheng, G., Yu, Z., Zhou, D.,
and Mattson, M. P. (2002).
Phosphatidylinositol-3-kinase-Akt
kinase and p42/p44 mitogen-
activated protein kinases mediate
neurotrophic and excitoprotective
actions of a secreted form of amy-
loid precursor protein. Exp. Neurol.
175, 407–414.
Cisse, M. A., Sunyach, C., Lefranc-
Jullien, S., Postina, R., Vincent, B.,
and Checler, F. (2005). The disinte-
grin ADAM9 indirectly contributes
to the physiological processing
of cellular prion by modulating
ADAM10 activity. J. Biol. Chem. 280,
40624–40631.
De Felice, F. G., Velasco, P. T., Lam-
bert, M. P., Viola, K., Fernan-
dez, S. J., Ferreira, S. T., et al.
(2007). Abeta oligomers induce neu-
ronal oxidative stress through an N-
methyl-d-aspartate receptor depen-
dent mechanism that is blocked by
the Alzheimer drug memantine. J.
Biol. Chem. 282, 11590–11601.
Dron, M., Moudjou, M., Chapuis, J.,
Salamat, M. K., Bernard, J., Cronier,
S., et al. (2010). Endogenous prote-
olytic cleavage of disease-associated
prion protein to produce C2 frag-
ments is strongly cell- and tissue-
dependent. J. Biol. Chem. 285,
10252–10264.
Dutta, S., Chiu, Y. C., Probert, A. W.,
and Wang, K. K. W. (2002). Selec-
tive release of calpain produced
αII-spectrin (α-fodrin) breakdown
products from acute neuronal cell
death. Biol. Chem. 383, 785–791.
Hachiya, N., Komata, Y., Harguem,
S., Nishijima, K., and Kaneko,
K. (2011). Possible involvement
of calpain-like activity in nor-
mal processing of cellular prion
protein. Neurosci. Lett. 490,
150–155.
Harris, D. A., Huber, M. T., van Dijken,
P., Shyng, S. L., Chait, B. T., and
Wang, R. (1993). Processing of a
cellular prion protein: identification
of N- and C-terminal cleavage sites.
Biochemistry 32, 1009–1016.
Hoglen, N. C., Chen, L. S.,
Fisher, C. D., Hirakawa, B. P.,
Groessl, T., and Contreras, P.





acid): a liver-targeted caspase
inhibitor. J. Pharmacol. Exp. Ther.
309, 634–640.
Hu, N. W., Klyubin, I., Anwy, R.,
and Rowan, M. J. (2009). GluN2B
subunit-containing NMDA receptor
antagonists prevent Abeta-mediated
synaptic plasticity disruption in vivo.
Proc. Natl. Acad. Sci. U.S.A. 106,
20504–20509.
Khosravani, H., Zhang, Y., Tsutsui, S.,
Hameed, S., Altier, C., Hamid, J.,
et al. (2008). Prion protein atten-
uates excitotoxicity by inhibiting
NMDA receptors. J. Cell Biol. 181,
551–565.
Kretzschmar, H. A., Prusiner, S. B.,
Stowring, L. E., and DeArmond,
S. J. (1986). Scrapie prion proteins
are synthesized in neurons. Am. J.
Pathol. 122, 1–5.
Linden, R., Martins, V. R., Prado, M. A.,
Cammarota, M., Izquierdo, I., and
Brentani, R. R. (2008). Physiology of
the prion protein. Physiol. Rev. 88,
673–728.
MacGregor, I., Hope, J., Barnard, G.,
Kirby, L., Drummond, O., Pepper, D.,
et al. (1999). Application of a time-
resolved fluoroimmunoassay for the
analysis of normal prion protein in
human blood and its components.
Vox Sang. 77, 88–96.
Moss, M. L., Powell, G., Miller, M. A.,
Edwards, L., Qi, B., Sang, Q. X., et al.
(2011). ADAM9 inhibition increases
membrane activity of ADAM10 and
controls alpha-secretase processing
of amyloid precursor protein. J. Biol.
Chem. 286, 40443–40451.
Moudjou, M., Frobert, Y., Grassi, J., and
LaBonnardiere, C. (2001). Cellular
prion protein status in sheep: tissue-
specific biochemical signatures. J.
Gen. Virol. 82, 2017–2024.
Pan, K.-M., Stahl, N., and Prusiner, S. B.
(1992). Purification and properties
of the cellular prion protein from
Syrian hamster brain. Protein Sci. 1,
1343–1352.
Parizek, P., Roeckl, C., Weber, J., Flech-
sig, E., Aguzzi, A., and Raeber, A. J.
(2001). Similar turnover and shed-
ding of the cellular prion pro-
tein in primary lymphoid and neu-
ronal cells. J. Biol. Chem. 276,
44627–44632.
Perini, F., Vidal, R., Ghetti, B., Tagli-
avini, F., Frangione, B., and Prelli, F.
(1996). PrP27-30 is a normal soluble
prion protein fragment released
by human platelets. Biochem.
Biophys. Res. Commun. 223,
572–577.
Riesner, D. (2003). Biochemistry and
structure of PrPC and PrPSc. Br.
Med. Bull. 66, 21–33.
Roberts, T. K., Eugenin, E. A., Morgello,
S., Clements, J. E., Zink, M. C.,
and Berman, J. W. (2010). PrPC,
the cellular isoform of the human
prion protein, is a novel biomarker
of HIV-associated neurocognitive
impairment and mediates neuroin-
flammation. Am. J. Pathol. 177,
1848–1860.
Frontiers in Neurology | Neurotrauma October 2012 | Volume 3 | Article 147 | 8
Wang et al. Neurotoxicity-induced neuronal PrPC release
Sales, N., Rodolfo, K., Hassig, R.,
Faucheux, B., Di Giamberardino, L.,
and Moya, K. L. (1998). Cellular
prion protein localization in rodent
and primate brain. Eur. J. Neurosci.
10, 2464–2471.
Shimazawa, M., Suemori, S., Inokuchi,
Y., Matsunaga, N., Nakajima, Y.,






1945), reduces murine retinal
cell death in vitro and in vivo. J.
Pharmacol. Exp. Ther. 332, 380–387.
Siman, R., McIntosh, T. K., Soltesz,
K. M., Chen, Z., Neumar, R. W.,
and Roberts, V. L. (2004). Proteins
released from degenerating neurons
are surrogate markers for acute brain
damage.Neurobiol. Dis. 16, 311–320.
Stein, T. D., Anders, N. J., DeCarli, C.,
Chan, S. L., Mattson, M. P., and
Johnson, J. A. (2004). Neutraliza-
tion of transthyretin reverses the
neuroprotective effects of secreted
amyloid precursor protein (APP)
in APPSW mice resulting in tau
phosphorylation and loss of hip-
pocampal neurons: support for the
amyloid hypothesis. J. Neurosci. 24,
7707–7717.
Tagliavini, F., Prelli, F., Porro, M.,
Salmona, M., Bugiani, O., and
Frangione, B. (1992). A soluble
form of prion protein in human
cerebrospinal fluid: implications
for prion-related encephalopathies.
Biochem. Biophys. Res. Commun.
184, 1398–1404.
Taraboulos, A., Scott, M., Semenov,
A., Avrahami, D., Laszlo, L., and
Prusiner, S. B. (1995). Choles-
terol depletion and modification of
COOH-terminal targeting sequence
of the priori protein inhibit forma-
tion of the scrapie isoforms. J. Cell
Biol. 129,121–132.
Taylor, D. R., Parkin, E. T., Cocklin,
S. L., Ault, J. R., Ashcroft, A. E.,
Turner, A. J., et al. (2009). Role of
ADAMs in the ectodomain shedding
and conformational conversion of
the prion protein. J. Biol. Chem. 284,
22590–22600.
Tousseyn, T., Thathiah, A., Jorissen,
E., Raemaekers, T., Konietzko, U.,
Reiss, K., et al. (2009). ADAM10, the
rate-limiting protease of regulated
intramembrane proteolysis of Notch
and other proteins, is processed
by ADAMS-9, ADAMS-15, and the
gamma-secretase. J. Biol. Chem. 284,
11738–11747.
Vincent, B., Paitel, E., Saftig, P., Frobert,
Y., Hartmann, D., De Strooper,
B., et al. (2001). The disintegrins
ADAM10 and TACE contribute to
the constitutive and phorbol ester-
regulated normal cleavage of the cel-
lular prion protein. J. Biol. Chem.
276, 37743–37746.
Wang, K. K. W. (2000). Calpain and
caspase: can you tell the difference?
Trends Neurosci. 23, 20–26.
Wang, K. K. W., Hajimohammadreza,
I., Raser, K. J., and Nath, R.
(1996). Maitotoxin induces calpain
activation in SH-SY5Y neuroblas-
toma cells and cerebrocortical cul-
tures. Arch. Biochem. Biophys. 331,
208–214.
Wang, X., Wang, F., Sy, M. S., and Ma,
J. (2005). Calpain and other cytoso-
lic proteases can contribute to the
degradation of retro-translocated
prion protein in the cytosol. J. Biol.
Chem. 280, 317–325.
Westergard, L., Christensen, H. M., and
Harris, D. A. (2007). The cellular
prion protein (PrPC): its physio-
logical function and role in dis-
ease. Biochim. Biophys. Acta. 1772,
629–644.
Wong, B. S., Pan, T., and Liu, T. (2000).
Differential contribution of super-
oxide dismutase activity by prion
protein in vivo. Biochem. Biophys.
Res. Commun. 273, 136–139.
Yadavalli, R., Guttmann, R. P., Seward,
T., Centers, A. P., Williamson, R. A.,
and Telling, G. C. (2004). Calpain-
dependent endoproteolytic cleavage
of PrPSc modulates scrapie prion
propagation. J. Biol. Chem. 279,
21948–21956.
You, H., Tsutsui, S., Hameed, S., Kan-
nanayakal, T. J., Chen, L., Xia,
P., et al. (2012). Abeta neuro-
toxicity depends on interactions
between copper ions, prion protein,
and N-methyl-d-aspartate recep-
tors. Proc. Natl. Acad. Sci. U.S.A. 109,
1737–1742.
Zhang, Z., Larner, S., Liu, M. C., Zheng,
W., Hayes, R. L., and Wang, K. K. W.
(2009). Multiple αII-spectrin break-
down products distinguish calpain
and caspase dominated necrotic and
apoptotic cell death pathways.Apop-
tosis 14, 1289–1298.
Zhang, Z., Mondello, S., Kobeissy,
F. H., Rubenstein, R., Streeter, J.,
Hayes, R. L., et al. (2011). Pro-
tein biomarkers for traumatic and
ischemic brain injury: from bench
to bedside. Transl. Stroke Res. 2,
455–462.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 07 August 2012; accepted: 01
October 2012; published online: 22 Octo-
ber 2012.
Citation: Wang KKW, Zoltewicz JS,
Chiu A, Zhang Z and Rubenstein
R (2012) Release of full-length PrPC
from cultured neurons following neuro-
toxic challenges. Front. Neur. 3:147. doi:
10.3389/fneur.2012.00147
This article was submitted to Frontiers in
Neurotrauma, a specialty of Frontiers in
Neurology.
Copyright © 2012 Wang , Zoltewicz,
Chiu, Zhang and Rubenstein. This is an
open-access article distributed under the
terms of the Creative Commons Attribu-
tion License, which permits use, distrib-
ution and reproduction in other forums,
provided the original authors and source
are credited and subject to any copy-
right notices concerning any third-party
graphics etc.
www.frontiersin.org October 2012 | Volume 3 | Article 147 | 9
